Expression and Hydroxylamine Cleavage of Thymosin Alpha 1 Concatemer

Liang Zhou, Zong-Teng Lai, Min-Kan Lu, Xing-Guo Gong, and Yi Xie

Room 345, College of Life Sciences, Zhejiang University, Hangzhou 310058, China

Correspondence should be addressed to Xing-Guo Gong, gongxg@zju.edu.cn

Received 3 December 2007; Revised 21 February 2008; Accepted 15 June 2008

Recommended by Nina Prak

Human thymosin alpha 1 (Tα1) is an important peptide in the development and senescence of immunological competence in human, and many studies have reported the expression of this peptide. In this study, we designed and synthesized the Tα1 gene according to the E. coli codon usage preference and constructed a 6×Tα1 concatemer. The latter was inserted into an E. coli expression vector pET-22b (+), and transformed into E. coli BL21 (DE3). After induction with IPTG, the concatemer protein was successfully expressed in E. coli then cleaved by hydroxylamine to release the Tα1 monomer. Gly-SDS-PAGE and mass spectrometry confirmed that the recombinant protein was cleaved as intended. The bioactivity of the Tα1 monomer was analyzed by lymphocyte proliferation and by mitochondrial activity in two different tumor cell lines. This study provides a description of the preparation of a bioactive Tα1, which may prove useful in future biomedical research.

Copyright © 2008 Liang Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Thymosin alpha 1 (Tα1), a 28-amino-acid peptide with molecular weight (MW) of 3108 Da, was first isolated from calf thymus in 1977 by Goldstein et al. [1, 2]. Tα1 is mainly produced in vivo by thymic epithelial cells and is stable at 80–90°C [3]. Tα1 has no aromatic amino acids (see Figure 1), and N-acetylation is important for protecting towards proteolysis. Tα1 plays a role against viral infection, against tumors, and in immunomodulation. Upon stimulation of Tα1, T cells become mature in vitro and express IL-2, IL-2R, and CD2 [4, 5]. Tα1 inhibits viral replication at least in hepatitis virus B-transfected HepG2 tumor cells [6, 7]. In addition, Tα1 antagonizes T cell apoptosis induced by dexamethasone, CD3 monoclonal antibody treatment [8], or addition of sera from tumor-bearing mice [9]. It also downregulates tumor weight in mice [10], enhances major histocompatibility complex (MHC) class I antigen expression in tumor cells and antigen-presenting cells [11–13], and partly restores cellular immunity [14]. Tα1 is used in combination with IFN-α for patients with chronic hepatitis virus B or C infection [15, 16]. Tα1 is used to reduce adverse effects from chemotherapy or radiotherapy [17]. Recently, Tα1 has even been used as an adjuvant for vaccines against influenza and hepatitis B [18].

In the past two decades, although the successful expression of the recombinant Tα1 (rTα1) and Prothymosin (thymosin comprises the N-terminus of Prothymosin) in Escherichia coli has been reported [19, 20]. However, Tα1 was expressed with a fusion protein or in a concatemer form [21, 22]. The expression of the Tα1 monomer peptide has not been reported, because it is difficult to extract the micromolecular peptide from the fermentation broth. The fusion protein must be removed because fusion protein could influence the bioactivity of the peptide. The concatemer protein has not been processed further. All of these issues made it difficult to prepare active recombinant Tα1. In this study, we have expressed Tα1 concatemer protein and cleaved the concatemer protein with hydroxylamine to obtain active Tα1 monomer peptide.

2. MATERIALS AND METHODS

2.1. Materials

The pET-22b (+) vector, E. coli BL21 (DE3) (hsdS gal [lacI857 ind1 Sam7 tin5 lacUV5-T7]), the HepG2 liver carcinoma cell line, and the SPC-A-1 lung carcinoma cell line were kindly provided by Institute of Biochemistry
and Cell biology (Shanghai, CAS, China). E. coli BL21 cells were maintained in Luria-Bertani (LB). HepG2 and SPC-A-1 cells were cultured in RPMI 1640 medium with 10% fetal bovine serum in humidified air at 37°C with 5% CO₂. Lymphocytes were isolated from adult mouse spleens (BAL/C) and cultured in RPMI 1640 medium with 10% fetal bovine serum in humidified air at 37°C with 5% CO₂. Synthesized Tα1 (Sinopep Pharmaceutical, Inc., Hangzhou, China.) was supplied as purified, endotoxin-free.

2.2. Synthesis of the Tα1 concatemer

Two single strand DNA oligomers encoding the entire thymosin alpha peptide (synthesized by Songon, Shanghai, China.), partially complementary to each other (as indicated by the underlined sequences) were synthesized. We used codons that were preferred in E. coli. 

THY-F: GTCGACATGGGATCCAACGGTTCT-GATGCTGCTGTAGATACTTCTTCTGAGAT
THY-R: CTCGAGTCAAGATCTCCCGTTCT-CAGCCTCTTCCGACAATCTCTTCTCTTCTCT

The 2 oligonucleotides were mixed and denatured by incubation at 94°C for 10 minutes, and subsequently annealed at 60°C for 10 minutes in presence of TaqPlus (BBI, Toronto, Canada). The desired double-strand DNA was treated with T4 polynucleotide kinase (BBI, Toronto, Canada). The desired double-strand DNA was ligated with T4 DNA Ligase (BBI, Toronto, Canada). The desired double-strand DNA was cloned into the cloning vector pUCm-T (BBI, Toronto, Canada).

The plasmid (pUCm-T-Tα1, pT-Tα1) containing the Tα1 gene was digested with BamHI/I or Bgl II/I to create the 2 fragments containing the coding sequence of Tα1 were ligated with T4 DNA Ligase for 16 hours at 4°C to produce the concatemer Tα1 gene of 2 repeats (pT-Tα1×2). When the plasmid was digested with isocaudamer BamHI (G∗CTAG C) and Bgl II (A∗GATC T), the 2 fragments had similar termini. When the 2 fragments were catalyzed with T4 DNA Ligase the new sequence formed was GGATCT, and this new site could not be digested by BamH I or Bgl II. Therefore, the new 2× concatemer gene could not be destroyed when the 4× concatemer gene was constructed. Thus, the plasmid containing 4×, 6× Tα1 genes could also be constructed.

Using a pT-Tα1×2 plasmid, plasmids containing concatemer 4 repeats (pT-Tα1×4) of the Tα1 gene were prepared as described above. Using a pT-Tα1×2 plasmid and a pT-Tα1×4 plasmid, the preparation of plasmids containing concatemer 6 repeats (pT-Tα1×6) was the same as pT-Tα1×2 plasmid.

Finally, a fragment containing the concatemer Tα1 gene of 6 repeats was constructed and inserted into expression vector pET-22b (+), between the restriction endonuclease recognition sites Hind III and Nde I.

2.3. Expression and purification of Tα1 concatemer protein

A single bacterial colony containing pET-22b (+)-Tα1 was grown overnight at 37°C in 5 mL LB medium with 50 μg/mL

![Figure 1: The complete amino acid sequence of Tα1.](image)

![Figure 2: Construction of the concatemer Tα1 gene. A T-vector containing the Tα1 gene was digested with BamHI/I or Bgl II/I to create the 2 fragments containing the coding sequence of Tα1 were ligated with T4 DNA Ligase for 16 hours at 4°C to produce the concatemer Tα1 gene of 2 repeats (pT-Tα1×2). When the plasmid was digested with isocaudamer BamHI (G∗CTAG C) and Bgl II (A∗GATC T), the 2 fragments had similar termini. When the 2 fragments were catalyzed with T4 DNA Ligase, the new sequence formed was GGATCT, and this new site could not be digested by BamH I or Bgl II. Therefore, the new 2× concatemer gene could not be destroyed when the 4× concatemer gene was constructed. Thus, the plasmid containing 4×, 6× Tα1 genes could also be constructed.]
Amicillin (BBI, Toronto, Canada). The overnight culture was inoculated into 250 mL LB medium in a 1 L flask with 50 μg/ml Amicillin. After 2 hours of incubation, isopropyl-1-thio-beta-D-galactoside (IPTG; BBI, Canada) was added to the culture at a final concentration of 1.0 mM, when the cell density had reached OD_600 nm = 0.6. After incubation at 37°C for 8 hours, the bacterial cells were harvested by centrifugation (5000 × g, 15 minutes) at 4°C. The inducibility of the concatemer gene was determined by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (data not shown).

The cell pellet was resuspended in 100 mL buffer A (50 mM Tris-HCl [pH 8.0], 1 mM EDTA [pH 8.0], and 0.1 M NaCl) and then sonicated (800 W, 20 minutes). After sonication, the sedimented material (containing the concatemer protein) was washed once first with 100 mL buffer B (50 mM Tris-HCl [pH 8.0], 1 mM EDTA [pH 8.0], and 0.5% Triton-X 100) and then with 100 mL buffer C (50 mM Tris-HCl [pH 8.0], 1 mM EDTA [pH 8.0], and 2 M urea) by centrifugation. The sedimented material was then dissolved in 100 mL buffer D (50 mM Tris-HCl [pH 8.0], 1 mM EDTA [pH 8.0], and 8 M urea) by centrifugation. The sedimented material was then used to prepare for the next step.

### 2.4. Hydroxylamine cleavage reaction and analysis of cleavage products

The concatemer protein was then cleaved with hydroxylamine. The cleavage sites are shown in Figure 3. The cleavage buffer [21] contained 0.1 M trizma base and 2.0 M hydroxylamine-HCl. The pH of the cleavage buffer was adjusted with 5 M NaOH solution to a pH of 9.0, and the reaction was performed at 45°C for 4 hours. The reaction was terminated by adjusting the pH to 4.0 with concentrated formic acid and cooling to 4°C [21]. Using Sephadex-G25 (GE) column chromatography, the products of cleavage were desalted. Column chromatography revealed 2 peaks; one peak corresponded to the Ta1 monomer and the other contained the incompletely cleaved concatemer protein. The molecular mass of the Ta1 monomer was analyzed by Gly-SDS-PAGE and mass spectrometry.

### 2.5. Assay for proliferation of mice splenic lymphocytes

The proliferation response of splenocytes was determined by MTT assay [23]. Spleens were removed from mice and dispersed through nylon mesh to generate a single-cell suspension. Cells were pelleted (1500 × g, 6 minutes), and the cell pellet was resuspended in erythrocyte lysis solution (0.15 M NH₄Cl, 0.02 M Tris, sterilized with a 0.22 μm filter) for 5 minutes to remove the red cells. After lysis, the cell suspension was incubated in a culture flask for 2 hours, and then the suspension was transferred to a new flask. Splenic macrophages adhered to the flask; this procedure enriched for lymphocytes.

Splenic lymphocytes were incubated in RPMI 1640 medium with 5 μg/mL concanavalin A (ConA; BBI, Canada) for 12 hours, and then harvested by centrifugation (1500 × g, 6 minutes). The cell pellet was resuspended in RPMI 1640 medium at a concentration of 1 × 10⁶ cells/mL. A 96-well culture plate (Costar, Inc., Calif, USA) was used for incubation of 180 μL lymphocytes in RPMI 1640 medium. 50 μg/mL of the proteins (cleaved Ta1 and synthesized Ta1) were added to the wells. After 24-hour or 48-hour incubation at 37°C, 20 μL of MTT (0.5 mg/mL), solution was added to each well, and the microplates were incubated for 4 hours at 37°C. After incubation, the plates were centrifuged (1400 × g, 18°C, 10 minutes). The supernatants were removed, and 200 μL of dimethyl sulfoxide (DMSO) was added to each well and incubated for 15 minutes at room temperature. After incubation, the solubilized reduced MTT was measured colorimetrically at 570 nm using a Benchmark microculture plate reader (Bio-Rad, Calif, USA).

### 2.6. Assay for mitochondrial activity of HepG2 and SPC-A-1 cells

The influence of Ta1 on mitochondrial activity was measured using MTT reduction, a common experimental method to quantify mitochondrial activity. The cells were seeded in a 96-well culture plate at 1 × 10⁶ cells/mL. After 24-hour, 48-hour, and 72-hour exposures to Ta1 and synthesized Ta1, 0.1 mM of the proteins (cleaved Ta1 and synthesized Ta1) were added to the wells. After 24-hour or 48-hour incubation at 37°C, 20 μL of MTT (0.5 mg/mL), solution was added to each well, and the microplates were incubated for 4 hours at 37°C. After incubation, the plates were centrifuged (1400 × g, 18°C, 10 minutes). The supernatants were removed, and 200 μL of dimethyl sulfoxide (DMSO) was added to each well and incubated for 15 minutes at room temperature. After incubation, the solubilized reduced MTT was measured colorimetrically at 570 nm using a Benchmark microculture plate reader (Bio-Rad, Calif, USA).

### 2.7. Statistic analysis

The data are presented as mean ± SEM, for at least 3 replicate experiments and evaluated using the Student’s t-test. P-values below 0.05 were regarded as statistically significance (two-tailed test).

### 3. RESULTS

Hydroxylamine-induced cleavage at the Asp-Gly dipeptide site inserted between the 2 moieties of recombinant fusion proteins had been used for both analysis and preparation of
mature protein. Cleavage occurs at the Asn-Gly bonds and results from the tendency of the Asp side chain to cyclize the formation of a substituted succinimide that is susceptible to nucleophilic attack by hydroxylamine. The infrequency of Asn-Gly bonds in most proteins results in the production of very large fragments that may overlap CNBr-produced fragments [24]. In the complete amino acid sequence of Tα1 [1] (see Figure 1), only 1 Asp was found at the C-terminus. However, the hydroxylamine-induced cleavage process was performed conveniently. Hydroxylamine-induced cleavage is high specificity and safe, however, the efficiency of hydroxylamine cleavage is low. So we expressed a concatemer protein of 6 repeats of Tα1 to increase the yield of Tα1 after cleavage and to decrease the cleavage sites.

3.1. Characterization of recombinant concatemer protein

The optimal conditions for inducing production of recombinant concatemer protein were at an IPTG concentration of 1.0 mM 37°C for 8 hours. Under these conditions, the recombinant protein (∼23 kD) comprised 31% of the total bacterial protein (see Figure 4(a)). The concatemer protein was identified primarily in the inclusion bodies (see Figure 4(b)).

3.2. Analysis of the products of hydroxylamine cleavage

G-25 column chromatography was used to not only desalt but also remove the incompletely cleaved concatemer protein. Because the molecular weight of the Tα1 monomer was ∼3.1 kD, it could enter the G-25 gel. However, the incompletely cleaved concatemer proteins, including 2×Tα1 (∼7 kD), 3×Tα1 (∼11 kD), 4×Tα1 (∼15 kD), 5×Tα1 (∼19 kD), and 6×Tα1 (∼23 kD), could not enter the G-25 gel because the gel only allows the entry of molecules <5 kD. The Gly-SDS-PAGE could satisfactorily separate polypeptides with molecular weights ranging from 3.5 to 68.0 kD with good linearity, and demonstrated the successful hydroxylamine-induced cleavage of the concatemer proteins (see Figure 5). However, not all the concatemer proteins were cleaved, and the incompletely cleaved proteins could be completely cleaved by another reaction (data not shown).

MS was performed to analyze the exact molecular weights of the products and the synthesized Tα1. The result showed that the products had only 1 peak of m/z = 1042.19, while the synthesized Tα1 had 2 peaks of m/z = 1037.80 and 1555.06 (see Figure 6). The molecular weight of the synthesized Tα1 was found to be approximately 3108 Da, it
was assumed that the peptide might attach 2 or 3 protons \([1037.80-1] \times 3 = 3110.4; \ (1555.06-1) \times 2 = 3108.12\].

Therefore, the cleaved Ta1 was believed to attach 3 protons, and the molecular weight of the products was approximately 3123.57 \([1042.19-1] \times 3 = 3123.57\]. The difference in the molecular weights between the cleaved Ta1 and the synthesized Ta1 was approximately 15. According to a previous research [24], the structural difference between the products and the synthesized Ta1 was a –NH added to the N-terminus of the cleaved peptide (see Figure 9).

### 3.3. Ta1 cleaved by hydroxylamine stimulated the proliferation of mice splenic lymphocytes

To determine the bioactivity of the Ta1 monomer on lymphocyte proliferation, the mitochondrial activity was compared in the presence with the absence of the Ta1. The bioactivity of Ta1 preparations was analyzed by MTT assay. Preliminary results showed that the peptides could stimulate the mice spleen lymphocyte proliferation [22]. After a 24-hour treatment with Ta1 cleaved by hydroxylamine, mitochondrial activity was upgraded to 119.1% and after 48 hours, it was 110.4%. The numbers of the synthesized Ta1 were 117.5% and 116.0% at 24 hours and 48 hours, respectively (see Figure 7). Both of the peptide preparations could stimulate the proliferation of mice spleen lymphocytes to a similar degree.

### 3.4. Ta1 cleaved by hydroxylamine exhibits decreased mitochondrial activity in SPC-A-1 and HepG2 cells

In this study, we used human liver tumor cells HepG2 and human lung tumor cells SPC-A-1 as model, because the liver tumor and lung tumor are the most general tumor. To determine the role of mitochondria during incubation, the mitochondrial activity was examined. After the treatment with the cleaved Ta1 for 24 hours, 48 hours, and 72 hours, the mitochondrial activity of the SPC-A-1 cells decreased to 82.4%, 27.1%, 11.6%, respectively, and the corresponding activities with synthesized Ta1 were 62.0%, 15.1%, and 9.8%, respectively. On the other hand, after the treatment for 24 hours, 48 hours, and 72 hours, the mitochondrial activity of HepG2 cells decreased to 86.6%, 18.4%, and 10.4%, respectively, and corresponding activities with the synthesized Ta1 were 59.2%, 13.1%, and 10.0%, respectively (see Figure 8). Both of the peptide preparations decreased the mitochondrial activity remarkably, as compared to the control. The difference in the activity between the 2 peptides was not significant; however, the process of synthesizing Ta1 was rather intricate.

### 4. DISCUSSION

The requirements of Ta1 for clinical applications are increasing. For clinical use, Ta1 is mainly obtained by chemical synthesis and animal thymus extraction. However, in fact, Ta1 from an animal is often impure and may therefore cause
Mitochondrial activity

Time (h)

Control

T synthesized

T cleaved

(a)

(b)

Figure 8: Ta1 (cleaved and synthesized) induced a decrease in the mitochondrial activity in the SPC-A 1 and HepG2 cells. (a) The SPC-A1 cells were treated with the indicated concentrations of Ta1 for 24 hours, 48 hours, and 72 hours. MTT assay was used to measure the mitochondrial activity. Significant decreases in the mitochondrial activity, as compared to the control, occurred after 48 hours of Ta1 treatment. (b) The HepG2 cells were treated with the indicated concentrations of Ta1 for 24 hours, 48 hours, and 72 hours. MTT assay was used to measure the mitochondrial activity. Significant decreases in the mitochondrial activity, as compared to the control, occurred after 48 hours of Ta1 treatment. All the results are expressed as the mean ± SEM of data obtained in 3 independent experiments (P < .05, relative to control).

NH₂ – CH₂ – CO–Ta1
CH₃ – CO–Ta1
(a) Cleaved Ta1
(b) Synthesized Ta1

Figure 9: Differences in the structures of the synthesized Ta1 and the cleaved Ta1.

heterogeneous allergy. Although chemically synthesized Ta1 can reach a high level of purity, it is necessary to eliminate the side products at each step, including incorrect joining and dextral compounds. The longer the peptide is, the more intricate the chemical synthesis process becomes. Ta1 comprises 28 amino acid residues, and its chemical synthesis incurs a high production cost [19]. Prokaryotic expression systems allow for high expression of foreign genes and are widely used for producing large amounts of proteins or peptides. In this research, using a prokaryotic expression system BL21 (DE3)/pET-22b (+), we have established a new method to obtain relatively pure and large quantities of Ta1.

When the plasmid was digested with isocaudamer BamHI (G*CTAG C) and Bgl II (A*GATC T), the 2 fragments had similar termini. When the 2 fragments were catalyzed with T4 DNA Ligase, the new sequence formed was GGATCT, and this new site could not be digested by BamHI or Bgl II (see Figure 2). Therefore, the new 2 × concatemer gene could not be destroyed when the 4 × concatemer gene was constructed. The new site GGATCT corresponded to the dipeptide Gly-Ser, located at the downstream of the Ta1 gene. When concatemer protein was cleaved with hydroxylamine, the downstream amino acid of Ta1 peptide was removed from this Gly site. When the cleavage reaction proceeded, the upstream amino acid of Ta1 peptide was removed from another Gly site, which was added in front of the Ta1 peptide.

It is common knowledge that extraction of the microscopic recombinant peptide from fermentation broth is difficult, when Ta1 is expressed alone. Generally, a fusion protein is used under these circumstances, for example, a DsbA fusion protein [25]. However, the fusion protein must be removed because the peptide might be inactive, and this process incurs a high production cost. The concatemer protein of 6 repeats—6×Ta1—was prepared in this research to avoid the use of a fusion protein when expressing the recombinant protein, but the number of the repeats was not unique. Proteins with 4, 8, 12, and so forth repeats could also be constructed. The longer the concatemer protein is, the greater the yield of the Ta1 monomer is. On the other hand, when a concatemer protein with more repeats is cleaved, the amount of the incompletely cleaved protein also increases (see Figure 5). However, these incompletely cleaved proteins can be cleaved by other 1 or 2 rounds of hydroxylamine cleavage.

Hydroxylamine was used to cleave the Asn-Gly peptide bond between the fusion protein and target protein [26]. In this study, hydroxylamine was used to cleave the concatemer protein of 6×Ta1 to release the Ta1 monomer. While chemical cleavage methods use relatively inexpensive and widely available reagents, cleavage conditions are often relatively harsh and amino acid side-chain modifications
may occur. This is especially true when hydroxylamine is used to cleave the Asn-Gly peptide linkages as other Asn or Gln residues can be modified to their hydroxamic acid forms [26]. Because the Ta1 peptide does not contain Gln, Met, or other Asn, chemical heterogeneity does not occur by conversion of the Gln or Asn to their hydroxamate forms. Moreover, there is no possibility of chemical heterogeneity by conversion of Met to its oxidized forms [27].

After hydroxylamine cleavage, a Gly remained at the N-terminus of Ta1. However, the natural Ta1 had an acetylated NH-terminal (see Figure 9). The molecular weight difference between the 2 groups was 15 Da, but there was no significant difference between the 2 bands revealed by the Gly-SDS-PAGE (see Figure 5). Hence, we used an MS to analyze the exact molecular weights of the 2 peptides. The result showed a difference was 15 Da (3123–3108 Da) (see Figure 6), indicating that the concatenomer protein was cleaved satisfactorily.

To investigate the influence of the extra imino group on the Ta1, we compared the antitumor and immunomodulation activities between the synthesized Ta1 and the cleaved Ta1. The results showed no significant difference between the 2 peptides. Furthermore, we found that Ta1 was able to depress the proliferation of HepG2 cells by downregulating the oxidative stress (data not shown). Jörnvall [28] had analyzed 40 known α-amino-acetylated polypeptide chains and postulated that acetylation occurs during an early posttranslational stage and may have particular importance in this regard. However, the structural or functional significance of the N-terminal acetylation of Ta1 is not known, and a protective function of acetylation with regard to proteolysis is possible [1]. The change in the N-terminus of cleaved peptides might not influence the bioactivity of Ta1; however, it might influence the stability in vivo.

In summary, Ta1 with a novel structure was prepared via the expression and hydroxylamine cleavage of a Ta1 concatenamer protein. This novel Ta1 could perform proliferation of mice splenic lymphocytes activities, identical to the natural Ta1. This study would provide the basis for the preparation of active Ta1 and other peptides.

ACKNOWLEDGMENT

This work was supported by a grant from National Innovation Fund for Technology, the Ministry of Science and Technology of China (no. 03C26213300586).

REFERENCES

[1] A. L. Goldstein, T. L. K. Low, M. McAdoo, et al., “Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 74, no. 2, pp. 725–729, 1977.

[2] T. L. K. Low, G. B. Thurman, M. McAdoo, et al., “The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin α1 and polypeptide β1 from calf thymus,” The Journal of Biological Chemistry, vol. 254, no. 3, pp. 981–986, 1979.

[3] C. S. Sarandeses, G. Covelo, C. Diaz-Jullien, and M. Freire, “Prothymosin α is processed to thymosin α1 and thymosin α11 by a lysosomal asparaginyl endopeptidase,” The Journal of Biological Chemistry, vol. 278, no. 15, pp. 13286–13293, 2003.

[4] A. P. Knutson, J. J. Freeman, K. R. Mueller, S. T. Roodman, and J. D. Bouhasin, “Thymosin-α1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model,” International Journal of Immunopharmacology, vol. 21, no. 1, pp. 15–26, 1999.

[5] K. D. Leichtling, S. A. Serrate, and M. B. Sztein, “Thymosin alpha 1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes,” International Journal of Immunopharmacology, vol. 12, no. 1, pp. 19–29, 1990.

[6] J. A. Mosher, M. G. Mutchnick, J. Dosescu, et al., “Thymosin-α1, but not interferon-α, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells,” Journal of Hepatology, vol. 25, no. 6, pp. 814–820, 1996.

[7] D. Bianco-Battles, C. W. Naylor, J. A. Mosher, J. Dosescu, and P. H. Naylor, “Clonal growth inhibition as a bioassay for thymosin alpha1: inactivation of Ta1 by trifluoroacetic acid,” Cellular and Molecular Biology, vol. 47, no. 1, pp. 157–160, 2001.

[8] C. A. Baumann, M. Badamchian, and A. L. Goldstein, “Thymosin α1, antagonizes dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways,” Mechanisms of Ageing and Development, vol. 94, no. 1–3, pp. 85–101, 1997.

[9] R. Roy, S. M. Singh, and A. Shanker, “Mechanism of thymocyte apoptosis induced by serum of tumor-bearing host: the molecular events involved and their inhibition by thymosin α-1,” International Journal of Immunopharmacology, vol. 22, no. 4, pp. 309–321, 2000.

[10] J. Beuth, J. M. Schierholz, and G. Mayer, “Thymosin α1 application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice,” Cancer Letters, vol. 159, no. 1, pp. 9–13, 2000.

[11] C. Giuliani, G. Napolitano, A. Mastino, et al., “Thymosin-α1 regulates MHC class I expression in FRTL-5 cells at transcriptional level,” European Journal of Immunology, vol. 30, no. 3, pp. 778–786, 2000.

[12] Y. Huang, Z. Chen, C. Zhou, H. Yao, M. Li, and C. Xu, “The modulation of thymosin alpha 1 in the maturation, differentiation and function of murine bone marrow-derived dendritic cells in the absence or presence of tumor necrosis factor-α,” International Immunopharmacology, vol. 4, no. 4, pp. 539–546, 2004.

[13] E. Tzehoval, M. B. Szteiu, and A. L. Goldstein, “Thymosins α1 and β1 potentiate the antigen-presenting capacity of macrophages,” Immunopharmacology, vol. 18, no. 2, pp. 107–113, 1989.

[14] J. W. Hadden, “Thymic endocrinology,” Annals of the New York Academy of Sciences, vol. 840, pp. 352–358, 1998.

[15] G. Rasi, P. Pierimarchi, P. Sinibaldi Vallebona, F. Colella, and E. Garaci, “Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma,” International Immunopharmacology, vol. 3, no. 8, pp. 1169–1176, 2003.

[16] S. Moscarella, G. Buzzelli, R. G. Romanelli, et al., “Interferon and thymosin combination therapy in naïve patients with chronic hepatitis C: preliminary results,” Liver, vol. 18, no. 5, pp. 366–369, 1998.
[17] E. Garaci, F. Pica, G. Rasi, and C. Favalli, “Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application,” *International Journal of Immunopharmacology*, vol. 22, no. 12, pp. 1067–1076, 2000.

[18] A. Billich, “Thymosin α1: SciClone Pharmaceuticals,” *Current Opinion in Investigational Drugs*, vol. 3, no. 5, pp. 698–707, 2002.

[19] P.-F. Chen, H.-Y. Zhang, G.-F. Fu, G.-X. Xu, and Y.-Y. Hou, “Overexpression of soluble human thymosin alpha 1 in *Escherichia coli*,” *Acta Biochimica et Biophysica Sinica*, vol. 37, no. 2, pp. 147–151, 2005.

[20] S. Yi, A. Brickenden, and W.-Y. Choy, “A new protocol for high-yield purification of recombinant human prothymosin α expressed in *Escherichia coli* for NMR studies,” *Protein Expression and Purification*, vol. 57, no. 1, pp. 1–8, 2008.

[21] H.-B. Park, S.-H. Pyo, S.-S. Hong, and J.-H. Kim, “Optimization of the hydroxylamine cleavage of an expressed fusion protein to produce a recombinant antimicrobial peptide,” *Biotechnology Letters*, vol. 23, no. 8, pp. 637–641, 2001.

[22] Y. Chen, L. Zhao, G. Shen, et al., “Expression and analysis of thymosin α1 concatemer in *Escherichia coli*,” *Biotechnology and Applied Biochemistry*, vol. 49, no. 1, pp. 51–56, 2008.

[23] L. Qiu, B. Y. Guo, H. Miao, et al., “Study on biological function of prothymosin a and its DNA microarray analysis,” *Academic Journal of Second Military Medical University*, vol. 23, no. 6, pp. 639–642, 2002.

[24] P. Bornstein and G. Balian, “Cleavage at Asn—Gly bonds with hydroxylamine,” *Methods in Enzymology*, vol. 47, pp. 132–145, 1977.

[25] C. Lin, X. Li, P. Wang, and J. Mei, “Construction and expression of recombinant human thymosin alpha 1,” *Journal of Zhejiang University of Technology*, vol. 33, no. 3, pp. 306–309, 2005.

[26] M. Antorini, U. Breme, P. Caccia, et al., “Hydroxylamine-induced cleavage of the asparaginyl–glycine motif in the production of recombinant proteins: the case of insulin-like growth factor I,” *Protein Expression and Purification*, vol. 11, no. 1, pp. 135–147, 1997.

[27] S. J. Milner, S. M. Thomas, F. J. Ballard, and G. L. Francis, “Optimization of the hydroxylamine cleavage of an expressed fusion protein to produce recombinant human insulin-like growth factor (IGF)-I,” *Biotechnology and Bioengineering*, vol. 50, no. 3, pp. 265–272, 1996.

[28] H. Jörnvall, “Acetylation of protein N-terminal amino groups structural observations on α amino acetylated proteins,” *Journal of Theoretical Biology*, vol. 55, no. 1, pp. 1–12, 1975.